Table 1.
Patients with OP
(n=39) |
Patients without OP (n=82) | P value | |
---|---|---|---|
Age (mean±SD) | 63.2±9.9 | 52.0±8.0 | 0.00 |
Duration of RA (mean±SD), years | 10.5±9.4 | 9.9±9.1 | 0.76 |
HAQ score (mean±SD) | 3.1±3.1 | 2.7±2.9 | 0.48 |
DAS 28 (mean±SD) | 3.35±1.27 | 3.20±1.19 | 0.6 |
Cumulative dose of glucocorticoids (gr) | 15.2±15.2 | 18.7±18.9 | 0.3 |
Usage of methotraxate (%) | 72.7% | 76.9% | 0.6 |
Menarche age (mean±SD), years | 13.4±1.5 | 13.6±1.7 | 0.73 |
Menopause age (mean±SD), years | 47.7±4.7 | 46.1±6.8 | 0.28 |
Serum calcium (mean±SD), mg/dl | 9.3±.58 | 9.2±.49 | 0.56 |
Serum ALK (mean±SD), mg/dl | 172.3±55.9 | 168.2±48.7 | 0.73 |
Urine 24 hours calcium (mean±SD), mg/24 h | 181.7±87.5 | 194.0±72.7 | 0.56 |
BMI (mean±SD), Kg/m2 | 28.0±7.2 | 30.85± 4.3 | 0.01 |
History of fracture, (N, percent) | 12 (30.8%) | 14 (17.1%) | 0.08 |
Use of calcium, (N, percent) | 31 (79.5%) | 68 (82.9%) | 0.65 |
Doing exercise, (N, percent) | 12 (9.9%) | 36 (29.8%) | 0.16 |
OP treatment, (N, percent) | 21 (53.8%) | 53 (64.6%) | 0.25 |
RF positive (N, percent) | 17 (58.6%) | 32 (45.1%) | 0.21 |
Anti CCP positive (N, percent) | 15 (71.4%) | 25 (50.0%) | 0.09 |